VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES

D. R. Naskhletashvili; Насхлеташвили Д. Р.; V. A. Gorbunova; Горбунова В. А.; A. Kh. Bekyashev; Бекяшев А. Х.; L. V. Demidov; Демидов Л. В.; G. Yu. Kharkevich; Харкевич Г. Ю.; S. M. Banov; Банов С. М.; I. V. Samoylenko; Самойленко И. В.; K. А. Baryshnikov; Барышников К. А.; K. V. Orlova; Орлова К. В.; I. А. Utyashev; Утяшев И. А.; N. N. Petenko; Петенко Н. Н.; I. G. Markina; Маркина И. Г.; E. A. Moskvina; Москвина Е. А.; S. V. Medvedev; Медведев С. В.

doi:10.17650/2222-1468-2016-6-4-30-34

VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES

Authors: Naskhletashvili D.R.¹, Gorbunova V.A.¹, Bekyashev A.K.¹, Demidov L.V.¹, Kharkevich G.Y.¹, Banov S.M.², Samoylenko I.V.¹, Baryshnikov K.А.¹, Orlova K.V.¹, Utyashev I.А.¹, Petenko N.N.¹, Markina I.G.¹, Moskvina E.A.¹, Medvedev S.V.¹
Affiliations:
1. N.N. Blokhin Russian Cancer Research Center
2. N.N. Burdenko Neurosurgery Research Institute
Issue: Vol 6, No 4 (2016)
Pages: 30-34
Section: DIAGNOSIS AND TREATMENT OF HEAD AND NECK TUMORS
Published: 08.12.2016
URL: https://ogsh.abvpress.ru/jour/article/view/248
DOI: https://doi.org/10.17650/2222-1468-2016-6-4-30-34
ID: 248

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

The effectiveness of traditional chemotherapy (with temozolomide, fotemustine, lomustine) alone or in combination with whole brain radiotherapy in melanoma patients with cerebral metastases does not exceed 7–10 % with no significant impact on survival, which is around 2–4 months. Targeted therapy helped to improve survival of patients with disseminated melanoma and BRAF V600 mutations. The use of targeted drugs in patients with brain metastases allows to control the tumor process and to succeed in treatment of cerebral metastases. According to currently available research data and our own results, the effectiveness of targeted therapy with vemurafenib in melanoma patients positive for BRAF V600 mutations with brain metastases reaches 18.0–44.5 % with median survival of 5.3–8.0 months. Evidences suggest that the use of vemurafenib in melanoma patients with brain metastases ensure effective disease control in most of the cases and has a significant advantage comparing to conventional chemotherapy and whole brain radiotherapy. According to the results of these studies vemurafenib can be recommended as a 1st line targeted drug for treatment of melanoma patients with BRAF V600 mutations and brain metastases. Despite the existence of blood-brain barrier and efflux systems, new targeted drugs showed promising results in treatment of brain metastases. Over the last few years we have enhanced our understanding of brain metastasis mechanisms, principles of blood-brain barrier functioning, and ways of cancer drugs penetration into the central nervous system. Targeted therapy is constantly developing and will play an increasing role in treatment of melanoma cerebral metastases in the future with finding of new targets.

Keywords

vemurafenib, melanoma, brain metastases, targeted therapy

16 4th Tverskaya-Yamskaya St., Moscow 125047

Russian Federation

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

VEMURAFENIB IN TREATMENT OF MELANOMA WITH BRAIN METASTASES

Full Text

Abstract

Keywords

About the authors

References

Supplementary files